Hematologic Malignancies in the Era of Immunotherapy - priME Oncology
Expert Perspectives
Expert Perspectives

Hematologic Malignancies in the Era of Immunotherapy

Clinician Perspectives

Not a member of My prIME? Join now for instant access.

Listen to a brief overview on key considerations for the current and future use of immunotherapy for the treatment of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Hodgkin lymphoma (HL), and multiple myeloma (MM). Compelling patient video snippets, faculty/participant discussion on practice challenges, and other unique features ensure an engaging learning experience

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.0 AMA PRA Category 1 Credit

Release Date

Release Date

Dec 21, 2017

Expiration Date

Dec 21, 2018

  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Andreas Engert, MDUniversity Hospital of Cologne
    Cologne, Germany
  • Michael J. Mauro, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Donna E. Reece, MDPrincess Margaret Hospital
    Toronto, Ontario, Canada

Multiple myeloma patient perspective
Yelak Biru

How I treat relapsed multiple myeloma in the era of immunotherapy
Donna E. Reece, MD

Hodgkin lymphoma patient perspective
Melissa Gonzalez

How I treat relapsed Hodgkin lymphoma: Can it be cured?
Andreas Engert, MD

Chronic myeloid leukemia patient perspective
Erin Ruddy

How I select and monitor treatment for chronic myeloid leukemia
Michael J. Mauro, MD

Acute myeloid leukemia patient perspective
Kristin Bourgeois

How I treat acute myeloid leukemia: The future of immunotherapy in leukemia
Jorge Cortes, MD

This educational activity is specifically designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Select optimal immunotherapy approaches, considering clinical safety and efficacy data for current and emerging treatments and combinations for patients with AML, CML, relapsed HL, and relapsed/refractory MM
  • Develop side-effect monitoring and management approaches for current and emerging treatments for AML, CML, relapsed HL, and relapsed/refractory MM, including the immune-related adverse events associated with immunotherapies
  • Identify promising clinical trials with novel therapies and combinations across the treatment landscape for AML, CML, relapsed HL, and relapsed/refractory MM
  • Engage patients and families in treatment decision making, by soliciting and incorporating their desires and goals for care

This educational activity is supported by a grant from Bristol-Myers Squibb.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Hematologic Malignancies in the Era of Immunotherapy - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Mr Biru has disclosed that he has received consulting fees from Celgene and Takeda.

Ms Bourgeois has disclosed that she has no relevant financial relationships to report.

Dr Cortes has disclosed that he has received consulting fees from and performed contracted research for Astellas, Bristol-Myers Squibb, Daiichi, Immunogen, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Engert has disclosed that he has received consulting fees from and performed contracted research for Amgen, Affimed, Bristol-Myers Squibb, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Ms Gonzalez has disclosed that she has no financial relationships to report.

Dr Mauro has disclosed that he has received consulting fees from Bristol-Myers Squibb and Pfizer. He also performed contracted research for Novartis Oncology (funding to institution). He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Reece has disclosed that she has received consulting fees from Amgen, Celgene, Janssen, and Takeda. She received research funding from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Otsuka, and Takeda. She also received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Otsuka, Takeda. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Ms Ruddy has disclosed that she has no financial relationships to report.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Elizabeth Cameron, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.